Core Viewpoint - Ademi LLP is investigating ARCA (NASDAQ: ABIO) for potential breaches of fiduciary duty and other legal violations related to its transaction with Oruka, where ARCA stockholders will own approximately 2.38% of the combined company, while Oruka stockholders will own about 97.62% [1][2] Group 1 - The investigation focuses on whether ARCA's board of directors is fulfilling their fiduciary duties to all shareholders [2] - Certain ARCA stockholders, holding approximately 28.5% of the outstanding shares, have entered into support agreements to vote in favor of the transaction and against alternative acquisition proposals [1] - ARCA insiders are expected to receive substantial benefits as part of the change of control arrangements [1]
Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka